News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,811 Results
Type
Article (42894)
Company Profile (437)
Press Release (669480)
Section
Business (208970)
Career Advice (2021)
Deals (36083)
Drug Delivery (104)
Drug Development (84306)
Employer Resources (171)
FDA (16515)
Job Trends (15102)
News (353854)
Policy (33158)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (9)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2649)
Accelerated approval (3)
Adcomms (26)
Allergies (81)
Alliances (51042)
ALS (83)
Alzheimer's disease (1383)
Antibody-drug conjugate (ADC) (118)
Approvals (16487)
Artificial intelligence (234)
Autoimmune disease (13)
Automation (14)
Bankruptcy (371)
Best Places to Work (11857)
BIOSECURE Act (19)
Biosimilars (98)
Biotechnology (330)
Bladder cancer (57)
Brain cancer (25)
Breast cancer (250)
Cancer (1917)
Cardiovascular disease (154)
Career advice (1685)
Career pathing (28)
CAR-T (142)
Cell therapy (405)
Cervical cancer (15)
Clinical research (67954)
Collaboration (766)
Compensation (431)
Complete response letters (23)
COVID-19 (2643)
CRISPR (38)
C-suite (200)
Cystic fibrosis (102)
Data (1808)
Decentralized trials (2)
Denatured (25)
Depression (44)
Diabetes (235)
Diagnostics (6379)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (113)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (75)
Earnings (87188)
Editorial (35)
Employer branding (21)
Employer resources (147)
Events (115211)
Executive appointments (623)
FDA (17544)
Featured Employer (56)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (679)
Gene editing (99)
Generative AI (19)
Gene therapy (287)
GLP-1 (713)
Government (4481)
Grass and pollen (4)
Guidances (47)
Healthcare (19149)
Huntington's disease (23)
IgA nephropathy (24)
Immunology and inflammation (106)
Indications (25)
Infectious disease (2767)
Inflammatory bowel disease (138)
Inflation Reduction Act (11)
Influenza (44)
Intellectual property (75)
Interviews (311)
IPO (16801)
IRA (43)
Job creations (3707)
Job search strategy (1434)
Kidney cancer (10)
Labor market (30)
Layoffs (478)
Leadership (15)
Legal (7987)
Liver cancer (73)
Lung cancer (277)
Lymphoma (127)
Machine learning (2)
Management (58)
Manufacturing (263)
MASH (60)
Medical device (13446)
Medtech (13451)
Mergers & acquisitions (19706)
Metabolic disorders (632)
Multiple sclerosis (67)
NASH (19)
Neurodegenerative disease (82)
Neuropsychiatric disorders (29)
Neuroscience (1863)
NextGen: Class of 2025 (6757)
Non-profit (4551)
Northern California (2306)
Now hiring (36)
Obesity (352)
Opinion (219)
Ovarian cancer (64)
Pain (77)
Pancreatic cancer (73)
Parkinson's disease (129)
Partnered (17)
Patents (190)
Patient recruitment (87)
Peanut (47)
People (58404)
Pharmaceutical (87)
Pharmacy benefit managers (19)
Phase I (21323)
Phase II (29955)
Phase III (22195)
Pipeline (881)
Podcasts (72)
Policy (112)
Postmarket research (2632)
Preclinical (9062)
Press Release (67)
Prostate cancer (91)
Psychedelics (37)
Radiopharmaceuticals (259)
Rare diseases (366)
Real estate (6012)
Recruiting (66)
Regulatory (22611)
Reports (43)
Research institute (2421)
Resumes & cover letters (351)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (69)
Series A (123)
Series B (75)
Service/supplier (11)
Sickle cell disease (54)
Southern California (2001)
Special edition (17)
Sponsored (29)
Startups (3761)
State (2)
Stomach cancer (15)
Supply chain (59)
The Weekly (46)
United States (20608)
Vaccines (662)
Venture capitalists (36)
Webinars (13)
Weight loss (243)
Women's health (33)
Worklife (15)
Date
Today (33)
Last 7 days (592)
Last 30 days (2964)
Last 365 days (35012)
2025 (6693)
2024 (36418)
2023 (41131)
2022 (52433)
2021 (56877)
2020 (55018)
2019 (47517)
2018 (35797)
2017 (33189)
2016 (32486)
2015 (38532)
2014 (32328)
2013 (27245)
2012 (29335)
2011 (29974)
2010 (28150)
Location
Africa (736)
Alabama (53)
Alaska (7)
Arizona (224)
Arkansas (13)
Asia (39302)
Australia (6539)
California (5340)
Canada (1815)
China (440)
Colorado (242)
Connecticut (266)
Delaware (121)
Europe (85952)
Florida (786)
Georgia (181)
Idaho (57)
Illinois (488)
India (22)
Indiana (285)
Iowa (8)
Japan (134)
Kansas (102)
Kentucky (24)
Louisiana (8)
Maine (60)
Maryland (817)
Massachusetts (4105)
Michigan (208)
Minnesota (362)
Mississippi (2)
Missouri (75)
Montana (29)
Nebraska (25)
Nevada (54)
New Hampshire (65)
New Jersey (1512)
New Mexico (30)
New York (1512)
North Carolina (949)
North Dakota (7)
Northern California (2306)
Ohio (184)
Oklahoma (13)
Oregon (37)
Pennsylvania (1203)
Puerto Rico (7)
Rhode Island (25)
South America (1110)
South Carolina (16)
South Dakota (1)
Southern California (2001)
Tennessee (87)
Texas (784)
Utah (163)
Virginia (125)
Washington D.C. (58)
Washington State (513)
West Virginia (3)
Wisconsin (48)
712,811 Results for "inhibitor therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
News
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
October 25, 2024
·
5 min read
Press Releases
ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
March 10, 2025
·
4 min read
BioCapital
Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University
Inhibitor Therapeutics, Inc. has entered into an exclusive, worldwide licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930 “New Angiogenesis Inhibitors”.
December 13, 2023
·
5 min read
Press Releases
Lilly to acquire Scorpion Therapeutics’ mutant-selective PI3Kα inhibitor program
January 14, 2025
·
6 min read
Press Releases
Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan
August 23, 2024
·
3 min read
Press Releases
Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
March 5, 2025
·
6 min read
Press Releases
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
February 20, 2025
·
6 min read
Business
Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board
At the forefront of the Inhibitor Therapeutics, Inc. pipeline is the use of Itraconazole to treat basal cell carcinomas in Basal Cell Carcinoma Nevus Syndrome aka Gorlin Syndrome.
December 19, 2023
·
9 min read
Press Releases
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
February 24, 2025
·
20 min read
Business
Melodia Therapeutics and Alivexis Sign Exclusive License Agreement for Cathepsin C Inhibitor Program MOD-A
Alivexis, Inc. and Melodia Therapeutics AG, a company established by Forty51 Ventures, announced that they have entered into an exclusive license agreement for the worldwide development, manufacturing, and commercialization of Alivexis’ MDI-0151, a novel Cathepsin C inhibitor with best-in-class potential.
June 21, 2024
·
3 min read
1 of 71,282
Next
